RUNX3基因启动子甲基化在非小细胞肺癌诊断的价值

摘要

目的 探讨检测RUNX3基因启动子甲基化在非小细胞肺癌(NSCLC)诊断的价值.方法 采用甲基化特异性聚合酶链反应,分析58例NSCLC组织和癌旁正常肺组织RUNX3基因启动子甲基化情况,分析其与临床病理特征的相关性.结果 58例中,NSCLC组织RUNX3基因启动子甲基化26例(44.8％),明显多于癌旁正常肺组织的10例(17.2％)(P＜0.01).RUNX3基因启动子甲基化与临床分期、淋巴结转移和分化程度密切相关(P＜0.05).结论 RUNX3基因启动子甲基化在NSCLC组织中有较高的检出率,并与其临床分期、淋巴结转移和分化程度相关,在NSCLC诊断和预后判断中具有重要的临床意义.%Objective To investigate the value of RUNX3 gene promoter methylation in diagnosis of non-small cellular lung cancer (NSCLC). Methods The methylation of RUNX3 gene promoter was analyzed in 58 NSCLC tissues and tumor-adjacent normal lung tissues by methylation-specific-PCR.The correlation between methylation of RUNX3 gene promoter and clinicopathological characteristics was statistically analyzed as well. Results Twenty-six (44.8%) tissues with methylation of RUNX3 gene promoter in 58 NSCLC tissues was detected, which was significantly higher than 10(17. 2%) tumor-adjacent normal lung tissues(P<0. 01). The methylation of RUNX3 gene promoter was closely related to clinical stage, lymph node metastasis and differentiation degree of NSCLC(P<0. 05). Conclusion The high methylation rate of RUNX3 gene promoter exists in NSCLC tissues. The methylation of RUNX3 gene promoter is closely related to clinical stage, lymph node metastasis and differentiation degree and has an important significance in the diagnosis and evaluation of prognosis of NSCLC.